For the study, researchers from Cleveland-based Case Western Reserve University conducted various mouse models to assess the therapeutic molecules’ ability to eliminate antibiotic-resistant bacteria.
The molecules attach to a protein responsible for making toxins in all Gram-positive bacterial species.
“Without the toxins, the bacteria become harmless. And since they don’t need the toxins to survive, there is less pressure to develop resistance,” senior study author Menachem Shoham, PhD, associate professor of biochemistry at Case Western Reserve University School of Medicine, said in a press release.
In one model, septic mice infected with methicillin-resistant Staphylococcus aureus demonstrated a 100 percent survival rate when treated with the molecules. In contrast, 70 percent of the untreated mice died. Researchers found the molecules offered similar efficacy to current antibiotics used to treat S. aureus.
“We have proven efficacy not only against MRSA but also against Staphylococcus epidermidis, which is notorious for clogging catheters, Streptococcus pyogenes that causes strep throat, Streptococcus pneumoniae and other pathogens,” Dr. Shoham said in the press release.
More articles on clinical leadership and infection control:
Hospital linens may be source of C. diff outbreaks, study finds
Ohio patient’s transplant surgery cancelled after Hurricane Michael
Colorado hospital installs NASA-inspired machine to aid in patients’ recoveries
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
